This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?
2026-06-03 17:35:00 ET
Last year, shares of Abivax (NASDAQ: ABVX) , a clinical-stage biotech company based in France, soared after it reported strong phase 3 results for its leading candidate, obefazimod, an investigational medicine for moderate-to-severe ulcerative colitis (UC). The company still had to wait for data from a maintenance study before seeking approval. Investors anxiously awaiting that development sent the stock price even higher in the meantime. However, Abivax recently reported somewhat disappointing data from this maintenance trial. The stock fell off a cliff as a result. Abivax's shares are still up about 1,000% over the past 12 months, but can the company deliver excellent returns from here on out?
Image source: Getty Images.
Let's start with what makes obefazimod so promising. While several immunosuppressants are highly effective at treating UC, because they weaken the body's immune system, they increase the risk of viral and bacterial infections. Obefazimod is being touted as a UC therapy that is not an immunosuppressant. It could prove highly effective while avoiding the traditional drawbacks of many of its competitors. Abivax provided evidence that obefazimod can achieve that goal in a phase 3 induction study.
NASDAQ: ABVX
ABVX Trading
17.52% G/L:
$82.85 Last:
4,169,906 Volume:
$81.26 Open:
